Navigation Links
Amgen's Denosumab and Eli Lilly's Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
Date:6/1/2009

Denosumab and Forteo/Forsteo Will Each Achieve Blockbuster Status in 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen's novel agent denosumab and Eli Lilly's parathyroid hormone (PTH) analogue Forteo/Forsteo (teriparatide) will drive robust 4.3 percent annual growth in the osteoporosis drug market from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Osteoporosis finds that concerns about the long-term safety of bisphosphonates -- which currently dominate the market -- will help convince primary care physicians and specialists to switch patients to PTH analogues and novel agents such as denosumab. The uptake of denosumab, which has a convenient dosage regimen of bi-annual subcutaneous injections, will drive the agent to achieve blockbuster sales of $2 billion in 2018 for the treatment of osteoporosis and osteopenia. The report also forecasts that Forteo/Forsteo will achieve blockbuster status in 2018 with sales of approximately $2 billion. Forteo/Forsteo's uptake will be achieved as a result of its efficacy in reducing the frequency of fractures as well as the prevalent safety concerns about the bisphosphonates.

The report also finds that that the launches of third-generation selective estrogen receptor modulators (SERMs), most notably Eli Lilly's arzoxifene, will drive market growth. Physicians will increasingly prescribe these agents, particularly if they demonstrate significant efficacy in reducing nonvertebral fractures.

"Interviewed experts indicate that arzoxifene is the most promising of the third-generation SERMs, as they believe it may be as efficacious as Pfizer's Fablyn without increasing mortality," said Decision Resources Analyst Jeremy Goldman, M.D. "If Phase III clinical trial data confirms this, we forecast that arzoxifene will become the market-leading SERM, generating sales of $600 million in 2018."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Virus Could Help Drive Obesity
2. Back to School Means Return of School Blood Drives
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
5. Customized virus kills brain tumor stem cells that drive lethal cancer
6. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
7. Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
8. Brain Defect Helps Drive Fragile X Syndrome
9. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
10. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
11. Disabilities Rising Among Workers; Need for Employer-Driven Disability Awareness, Support Efforts Also Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... , ... March 25, 2017 , ... Getting earned media ... public relations partner. , All through the year, Garden Media aims to provide ... working with key influencers and pitching client’s key messages to gain coveted ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The iaedp ... and other medical professionals caring for those suffering from the full spectrum of disordered ... 800, as eating disorders professionals from nearly all 50 states and several countries converged ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... of enhancements, upgrading their training and leads programs. , In February, 2017, Empower ... elite sales agents, Performance Partners is designed to teach how to maximize their ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to gain popularity. A ... market will reach a value of USD 55.8 billion by 2025. ... growing industry. By the end of 2016, 28 states have now laws ... conservative states like Arkansas and North ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology: